menu
    • menu
    [{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Tetra BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Antibe Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"APOPHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ademetionine","moa":"Methionine metabolism","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Pharmtechnology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"GIC-1001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"JDP-205","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."}]

    Find Clinical Drug Pipeline Developments & Deals by Algorithme Pharma Inc.

    Menu

    Algorithme Pharma Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ademetionine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : MSI Methylation Sciences Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine

                            Details : Ademethionine is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            November 10, 2020

                            Lead Product(s) : Ademetionine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : MSI Methylation Sciences Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Tetra BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers

                            Details : PPP001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 08, 2020

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Tetra BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Pharmtechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fastin...

                            Details : Telmisartan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 15, 2018

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Pharmtechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects

                            Details : ATB-346 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2017

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : APOPHARMA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

                            Details : Deferiprone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 13, 2015

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : APOPHARMA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIC-1001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Gicare Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

                            Details : GIC-1001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 28, 2014

                            Lead Product(s) : GIC-1001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Gicare Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JDP-205

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : TerSera Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg

                            Details : JDP-205 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urticaria.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 31, 2013

                            Lead Product(s) : JDP-205

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : TerSera Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of Metronidazole Capsules Under Fasting Conditions

                            Details : Metronidazole is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 27, 2011

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Algorithme Pharma Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of Metronidazole Capsules Under Fed Conditions

                            Details : Metronidazole is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 27, 2011

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Par Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth